Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Rafarma Pharmaceuticals, Inc. (RAFA) Is A Solid Ship On A Rising Sea 0 comments
    Aug 30, 2013 10:17 AM

    One investment rule of thumb is to look for a solid ship on a rising sea. In this case, the rising sea is the Russian pharmaceutical industry, driven by a need that is clearly recognized by the Russian government. The government is actively encouraging the growth of the domestic pharmaceutical industry, with specific support for selected companies to foster the growing production of both basic and innovative drugs, all in a move to reduce the country's dependence on foreign medicines.

    The efforts of the government, together with a clear market need, have pushed the overall Russian pharmaceutical industry to record growth, and it is now expected to top $10 billion by 2014, and some say as much as $60 billion by 2020, with biotech R&D playing a significant role. Various areas around the country have become focal points for this drive, and a number of U.S. and European pharmaceutical companies are either moving or building research and production facilities in Russia to take advantage of growing market opportunities and a generally supportive climate. Russia has become an especially popular place to pursue clinical trials, given its reputation for both financial support and the expediting of the trial process.

    The "solid ship" in this picture is Rafarma Pharmaceuticals, relatively new but already one of the leading research companies in the Russian pharmaceutical industry. Rafarma is positioned to benefit from federal initiatives, and by 2018 the company intends to be one of the top players in the Russian pharmaceutical market, producing a range of generic and alternative basic pharmaceutical products available for sale at "mass market" prices. The company has been listed as one of the leading and most prospective projects in the modern Russian pharmaceutical and medical industry. Rafarma considers itself on track to saturate the Russian market as a European-based specialist pharmaceutical producer. The company is also securing its foothold to penetrate international markets such as Brazil and the Southeast Asian sub-continent.

    For more information, visit Rafarma.us

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.